Pharmaceuticals

Spinal Muscular Atrophy Treatment Market 2026–2035 expanding with gene therapy breakthroughs

March 25, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Expansion Is Predicted For The Spinal Muscular Atrophy Treatment Market Between 2026 And 2030?

The spinal muscular atrophy treatment market has experienced substantial expansion in its size over recent years. This market is projected to expand from $5.1 billion in 2025 to reach $5.89 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 15.5%. Historically, this growth has been linked to factors such as restricted therapeutic choices for SMA, insufficient public understanding of genetic conditions, a dependence on hospital-centric care, the gradual integration of novel treatments, and the absence of comprehensive early diagnosis initiatives.

The spinal muscular atrophy treatment market is projected to experience swift expansion over the coming years. By 2030, its size is predicted to reach $10.38 billion, demonstrating a compound annual growth rate (CAGR) of 15.2%. This anticipated growth during the forecast period is driven by factors such as the advancement of sophisticated gene therapies, increased funding for SMA research, expanded newborn screening programs, the proliferation of specialized clinics and homecare options, and the incorporation of digital health and telemedicine technologies. Key trends foreseen in this period encompass the growing acceptance of gene therapy and SMN2-modifying therapies, a heightened emphasis on prompt diagnosis and newborn screening protocols, an increase in homecare and specialized clinic-based SMA management, the enlargement of multidisciplinary care teams assisting SMA patients, and the widespread adoption of telehealth alongside remote patient monitoring.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24714&type=smp

What Key Drivers Are Influencing The Growth Of The Spinal Muscular Atrophy Treatment Market?

The spinal muscular atrophy treatment market is anticipated to expand due to increasing attention on gene therapy. This medical technique, gene therapy, entails altering an individual’s genetic material (DNA or RNA) for disease treatment or prevention. The heightened interest in gene therapy stems mainly from its capacity to address the fundamental cause of genetic disorders by directly adjusting or substituting defective genes, providing sustained or lasting therapeutic outcomes unlike conventional therapies. Treatments for spinal muscular atrophy benefit from gene therapy, exemplified by onasemnogene abeparvovec (Zolgensma), which offers a single, targeted method to deliver a working SMN1 gene copy, substantially enhancing motor function and patient quality of life for those with SMA. As an illustration, the American Society of Gene and Cell Therapy, a US-based entity, reported in January 2024 that gene therapies undergoing Phase III trials saw a 10% rise in the fourth quarter of 2023 compared to the previous quarter, marking the initial such increase since the third quarter of 2022. Consequently, the increasing emphasis on gene therapy is a key driver for the expansion of the spinal muscular atrophy treatment market.

Which Market Segments Are Examined In The Spinal Muscular Atrophy Treatment Market Study?

The spinal muscular atrophy treatment market covered in this report is segmented –

1) By Treatment: Medication, Physical Therapy, Surgery, Other Treatments

2) By Type: Werdnig-Hoffmann Disease, Infant Spinal Muscular Atrophy, Kugelberg-Welander Disease, Adult Spinal Muscular Atrophy

3) By Route Of Administration: Oral, Parenteral

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Medication: Nusinersen (Spinraza), Onasemnogene Abeparvovec-Xioi (Zolgensma), Risdiplam (Evrysdi), Antisense Oligonucleotides, Spinal Muscular Atrophy (SMN2) Splicing Modifiers, Corticosteroids, Supportive Medications

2) By Physical Therapy: Occupational Therapy, Respiratory Therapy, Aquatic Therapy, Orthotic Support, Assistive Mobility Devices, Range-Of-Motion Exercises

3) By Surgery: Spinal Fusion Surgery, Scoliosis Correction Surgery, Orthopedic Surgery, Gastrostomy Tube Placement, Tracheostomy

4) By Other Treatments: Nutritional Support, Respiratory Support, Psychosocial Support And Counseling, Genetic Counseling, Stem Cell Therapy

Which Trends Are Influencing The Spinal Muscular Atrophy Treatment Market?

Major companies operating in the spinal muscular atrophy treatment market are concentrating on developing innovative formulations, such as survival motor neuron 2 (SMN2) splicing modifier tablets, to enhance motor function and slow the advancement of the disease. These survival motor neuron 2 (SMN2) splicing modifier tablets are oral medications engineered to alter the splicing of the SMN2 gene, which facilitates the production of functional SMN protein crucial for motor neuron survival. By increasing the levels of full-length SMN protein, these tablets contribute to treating spinal muscular atrophy (SMA), thereby improving muscle function and decelerating disease progression. For example, in February 2025, Genentech, Inc., a US-based biotechnology company, obtained U.S. Food and Drug Administration approval for its Evrysdi (risdiplam) tablet, which is the first and only non-invasive SMN2 splicing modifier tablet approved for the treatment of SMA. The Evrysdi tablet provides comparable efficacy and safety to the existing oral solution, along with added benefits such as room-temperature storage and simplified administration for patients aged 2 years and older who weigh more than 44 lbs (20 kgs), offering greater convenience and flexibility in managing the condition.

Who Are The Primary Competitors In The Spinal Muscular Atrophy Treatment Market?

Major companies operating in the spinal muscular atrophy treatment market are F. Hoffmann-La Roche Ltd, Novartis AG, Biogen Inc., Ionis Pharmaceuticals Inc., Chugai Pharmaceutical Co. Ltd, PTC Therapeutics Inc., Voyager Therapeutics Inc., Scholar Rock Holding Corporation, Genethon, Exegenesis Bio Inc., Alcyone Therapeutics Inc., Biophytis SA, Ractigen Therapeutics, Sarepta Therapeutics Inc., Astellas Pharma Inc., Pfizer Inc., AstraZeneca PLC, Roche Molecular Systems Inc., Avexis Inc., Cytokinetics Incorporated, Repligen Corporation, Neurogene Inc., Solid Biosciences Inc., Entrada Therapeutics Inc., Regenxbio Inc., Rocket Pharmaceuticals Inc., Asklepios BioPharmaceutical (AskBio) Inc., Ultragenyx Pharmaceutical Inc., Catalyst Pharmaceuticals Inc., NMD Pharma A/S, Biohaven Pharmaceutical Holding Company Ltd, Vybion Inc., Apteeus SAS, BIOCAD INDIA PRIVATE LIMITED

Read the full spinal muscular atrophy treatment market report here:

https://www.thebusinessresearchcompany.com/report/spinal-muscular-atrophy-treatment-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Spinal Muscular Atrophy Treatment Market?

North America was the largest region in the spinal muscular atrophy treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the spinal muscular atrophy treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Spinal Muscular Atrophy Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24714&type=smp

Browse Through More Reports Similar to the Global Spinal Muscular Atrophy Treatment Market 2026, By The Business Research Company

Spinal Surgery Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/spinal-surgery-devices-and-equipment-global-market-report

Cerebrospinal Fluid Management Csf Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/cerebrospinal-fluid-management-csf-devices-and-equipment-global-market-report

Spinal Imaging Market Report 2026

https://www.thebusinessresearchcompany.com/report/spinal-imaging-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795